Research Progress on Intravenous Thrombolytic Therapy for Ischemic Stroke

卒中是一种有着高致残率、高复发率、高死亡率的常见疾病，静脉溶栓是急性缺血性卒中患者目前最容易获得和最有效的再灌注疗法，尽快开通血管、恢复血流、挽救缺血半暗带，尽可能地减少缺血性卒中的致残率和死亡率，静脉溶栓治疗提高了良好功能结局的比例，且出血并发症的风险极低。随着新型溶栓药物的出现，治疗从时间窗逐渐向组织窗过渡，在特殊患者是否溶栓中权衡利弊，因此本论文对急性缺血性卒中的应用及最新进展进行综述讨论。Stroke is a common disease characterized by high disability, recurrence, and mortality rates. Intravenous thrombolysis (IVT) is currently the most accessible and effective reperfusion therapy for acute ischemic stroke (AIS). It aims to rapidly restore blood flow, salvage the ischemic penumbra, and minimize disability and mortality. IVT improves the likelihood of favorable functional outcomes with a low risk of hemorrhagic complications. With the emergence of novel thrombolytic agents, the treatment paradigm is gradually shifting from a strict time window to a tissue window approach, requiring careful risk-benefit assessment in specific patient populations. This review discusses the application and latest advances in IVT for AIS.